Remission Rate of Pemphigus Vulgaris and Pemphigus Foliaceus in the Institute of Dermatology: A 7 Years Retrospective Study
DOI:
https://doi.org/10.59796/jcst.V14N2.2024.40Keywords:
pemphigus vulgaris (PV), pemphigus foliaceus (PF), remission rate of pemphigus, oral prednisolone treatment, antiCD-20 monoclonal antibody, IVIGAbstract
Pemphigus, an autoimmune blistering disease caused by autoantibodies targeting desmoglein 1, desmoglein 3, and desmosomal cadherins, is characterized by blister formation and can be a long-term condition with the possibility of relapse. This study aimed to evaluate the remission rates and compare them between pemphigus vulgaris (PV) and pemphigus foliaceus (PF) at the Institute of Dermatology. A retrospective analysis was conducted on 426 patients diagnosed and treated at the Institute of Dermatology in Bangkok, Thailand, between January 1, 2016, and December 31, 2022, for PV and PF. Patients were followed up for 1, 2, and 5 years to assess complete remission using Consensus statement criteria. The remission rates for PV and PF were 3.3%, 17.5%, and 48.4% at 1, 2, and 5 years, and 7.9%, 33.1%, and 61.6% at the same intervals, respectively. PF demonstrated significantly higher remission rates compared to PV at all time points (p< .001). The average time to remission was 60 months for PV and 36 months for PF. Prognostic factors associated with complete remission included age, age at onset, control of underlying disease, disease severity, primary site of involvement, and initial mucosal involvement. In conclusion, the remission rates for PV and PF at five years were 48.4% and 61.6%, respectively. PF achieved complete remission more frequently than PV. Good control of underlying disease, absence of initial mucosal involvement, and mild disease severity were associated with better prognosis for both PV and PF.
References
Ahmed, A. R. (1983). Clinical features of pemphigus. Clinics in Dermatology, 1(2), 13-21. https://doi.org/10.1016/0738-081x(83)90020-2
Almugairen, N., Hospital, V., Bedane, C., Duvert-Lehembre, S., Picard, D., Tronquoy, A. F., ... & Joly, P. (2013). Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium-and high-dose corticosteroids. Journal of the American Academy of Dermatology, 69(4), 583-588. https://doi.org/10.1016/j.jaad.2013.05.016
Aoki, V., Millikan, R. C., Rivitti, E. A., Hans-Filho, G., Eaton, D. P., Warren, S. J., ... & Diaz, L. A. (2004). Environmental risk factors in endemic Pemphigus foliaceus (Fogo selvagem). Journal of Investigative Dermatology Symposium Proceedings, 9(1), 34-40. https://doi.org/10.1111/j.1087-0024.2004.00833.x
Barthelemy, H., Frappaz, A., Cambazard, F., Mauduit, G., Rouchouse, B., Kanitakis, J., ... & Thivolet, J. (1988). Treatment of nine cases of pemphigus vulgaris with cyclosporine. Journal of the American Academy of Dermatology, 18(6), 1262-1266. https://doi.org/10.1016/s0190-9622(88)70132-2
Bastuji-Garin, S., Souissi, R., Blum, L., Turki, H., Nouira, R., Jomaa, B., ... & Kamoun, M. R. (1995). Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. Journal of investigative dermatology, 104(2), 302-305. https://doi.org/10.1111/1523-1747.ep12612836
Bystryn, J. C. (1984). Adjuvant therapy of pemphigus. Archives of dermatology, 120(7), 941-951. https://doi.org/10.1001/archderm.1984.01650430127024
Cura, M. J., Torre, A. C., Sarmiento, K. C., Garlatti, M. B., Riganti, J., Puga, M. C., & Mazzuoccolo, L. D. (2020). Pénfigo vulgar: estudio de cohorte retrospectivo de sus características clínicas, tratamientos empleados y evolución. Actas Dermo-Sifiliográficas, 111(5), 398-407. https://doi.org/10.1016/j.ad.2019.10.004
Herbst, A., & Bystryn, J. (2000). Patterns of remission in pemphigus vulgaris. Journal of the American Academy of Dermatology, 42(3), 422–427. https://doi.org/10.1016/s0190-9622(00)90213-5
Joly, P., Horvath, B., Patsatsi, Α., Uzun, S. O. N. E. R., Bech, R., Beissert, S., ... & Schmidt, E. (2020). Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 34(9), 1900-1913. https://doi.org/10.1111/jdv.16752
Kulthanan, K., Chularojanamontri, L., Tuchinda, P., Sirikudta, W., & Pinkaew, S. (2011). Clinical features and courseof pemphigus in Thai patients. Asian Pacific journal of allergy and immunology, 29(2), 161–168.
Krain, L. S. (1974). Pemphigus. Epidemiologic and survival characteristics of 59 patients, 1955-1973. Archives of Dermatology, 110(6), 862–865. https://doi.org/10.1001/archderm.110.6.862
Lapidoth, M., David, M., Ben‐Amitai, D., Katzenelson, V., Lustig, S., & Sandbank, M. (1994). The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: Preliminary study. Journal of the American Academy of Dermatology, 30(5), 752–757. https://doi.org/10.1016/s0190-9622(08)81506-x
Murrell, D. F., Dick, S., Ahmed, A. R., Amagai, M., Barnadas, M. A., Borradori, L., ... & Werth, V. P. (2008). Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. Journal of the American Academy of Dermatology, 58(6), 1043–1046. https://doi.org/10.1016/j.jaad.2008.01.012
Murrell, D. F., Peña, S., Joly, P., Marinovic, B., Hashimoto, T., Diaz, L. A., ... & Werth, V. P. (2020). Diagnosis and management of pemphigus: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology, 82(3), 575-585. https://doi.org/10.1016/j.jaad.2018.02.021
Piamphongsant, T. (1979). Treatment of Pemphigus with corticosteroids and cyclophosphamide. The Journal of Dermatology, 6(6), 359–363. https://doi.org/10.1111/j.1346-8138.1979.tb01927.x
Pisanti, S., Sharav, Y., Kaufman, E. J., & Posner, L. (1974). Pemphigus vulgaris: Incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surgery, Oral Medicine, Oral Pathology, 38(3), 382–387. https://doi.org/10.1016/0030-4220(74)90365-x
Rosi‐Schumacher, M., Baker, J. D., Waris, J., Seiffert-Sinha, K., & Sinha, A. A. (2023). Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Frontiers in Immunology, 14, Article 1159351. https://doi.org/10.3389/fimmu.2023.1159351
Salmanpour, R. A., Shahkar, H., Namazi, M. R., & Rahman‐Shenas, M. R. (2004). Epidemiology of pemphigus in south‐western Iran: A 10‐year retrospective study (1991–2000). International Journal of Dermatology, 45(2), 103–105. https://doi.org/10.1111/j.1365-4632.2004.02374.x
Seidenbaum, M., David, M., & Sandbank, M. (1988). The course and prognosis of Pemphigus. International Journal of Dermatology, 27(8), 580–584. https://doi.org/10.1111/j.1365-4362.1988.tb02409.x
Sevadjian, C. M. (1979). Nosology of Brazilian pemphigus foliaceus. International Journal of Dermatology, 18(10), 781–786. https://doi.org/10.1111/j.1365-4362.1979.tb04464.x
Tsankov, N., Vassileva, S., Kamarashev, J., Kazandjieva, J., & Kuzeva, V. (2000). Epidemiology of pemphigus in Sofia, Bulgaria. A 16‐year retrospective study (1980–1995). International Journal of Dermatology, 39(2), 104–108. https://doi.org/10.1046/j.1365-4362.2000.00864.x
Uzun, S., Durdu, M., Akman, A., Günaştı, S., Uslular, C., Memişoğlu, H. R., & Alpsoy, E. (2004). Pemphigus in the Mediterranean region of Turkey: A study of 148 cases. International Journal of Dermatology, 45(5), 523–528. https://doi.org/10.1111/j.1365-4632.2004.02533.x
Warren, S. J., Lin, M. S., Giudice, G. J., Hoffmann, R. G., Hans-Filho, G., Aoki, V., ... & Diaz, L. A. (2000). The Prevalence of Antibodies against Desmoglein 1 in Endemic Pemphigus Foliaceus in Brazil. The New England Journal of Medicine, 343(1), 23–30. https://doi.org/10.1056/nejm200007063430104
Downloads
Published
How to Cite
License
Copyright (c) 2024 Journal of Current Science and Technology
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.